产品名称：Dostarlimab
中文名称：多塔利单抗
产品别称：TSR-042, ANB-011
靶点：PD1 [Homo sapiens]
抗体亚型：IgG4 - kappa
来源：CHO DG44 cells
体内研究：在人源化PD-1小鼠肿瘤模型中，Dostarlimab展示出抗肿瘤活性[1]。
| Animal Model | humanized mouse models representative of human non–small cell lung cancer and breast cancer |
| Dosage | 200 µg/mouse |
| Result | Inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination）；The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8+ T cells; Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%). |
参考文献：1.Kumar S, Ghosh S, Sharma G, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021;13(1):1954136. doi:10.1080/19420862.2021.1954136
仅供科研使用
